Rising prevalence of anaphylaxis and increasing healthcare spending are some of the key drivers for the global market growth. Additionally, emerging biologic drug therapies, minimized needle-stick injuries and growing aging population also support the growth of the global market.

In terms of therapeutic application, the auto-injectors market is segmented into anaphylaxis, multiple sclerosis, rheumatoid arthritis and others. The other applications include migraine, psoriasis and diabetes. Among the therapeutic application, the anaphylaxis segmented contributed to almost 88% of the overall market for auto-injectors in 2016. Some of the major factors driving the growth of this application include, increasing prevalence of anaphylaxis globally and rising awareness about the auto-injectors for treating various allergies effectively.

Request to Get the Sample Pages at: https://www.psmarketresearch.com/market-analysis/auto-injectors-market/report-sample

The increasing prevalence of these various chronic diseases has led to rising government and non-government initiatives which in turn has led to increased healthcare spending globally. Rise in affordability and accessibility of advanced healthcare solutions has further led to high healthcare spending. According to the World Health Organization (WHO), the total healthcare expenditure has increased globally, leading to high healthcare infrastructure and increased use of advanced healthcare devices such as pens, auto-injectors, wearable injectors for self-medication by patients suffering from anaphylaxis, diabetes, multiple sclerosis, migraine and rheumatoid arthritis. The demand for self-injection devices has been increasing with the increasing prevalence of such diseases which require daily or weekly doses and hence, supporting the growth of the global auto-injectors market.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=auto-injectors-market

The major players in the auto-injectors market are launching new products to improve their position in the market. For instance, in December 2016, Mylan N V launched generic Cerebyx injection for the treatment of several different type of seizures. The product is part of Mylan's growing global portfolio of more than 450 injectable products, which includes liquid, lyophilized and dry-powder formulations delivered in a range of mechanisms including ampoules, vials, ready-to-use bags and pre-filled syringes.

Some of the key players operating in the auto-injectors market include Mylan N.V., Antares Pharma Inc., Becton, Dickinson & Co., Eli Lilly and Company, Pfizer, Inc., Bayer AG, Novartis International AG, Bristol-Myer Squibb, Novartis AG, Amgen Inc. and Biogen Inc.